X
Pharma Advancement
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Robots and AI in Drug

    Robots and AI in Drug Discovery Are Transforming Medicine

    Stringent Policy around COVID Vaccines Laid by FDA

    Stringent Policy around COVID Vaccines Laid by FDA

    Pharmaceutical-Chemicals Market Booms with Rising API Demand

    Pharmaceutical Chemicals Market Booms with Rising API Demand

    Next in Pharma 2025 Innovations

    Next in Pharma 2025: Innovations Shaping the Future

    Work Smart: Go for Hands-Free Lab Informatics at the Bench, Not Scribbled Notes and Delayed Documentation at Your Desk

    Clinical Development

    AI Revolutionizing Drug Discovery and Clinical Development

    Drug-Development

    China’s Super Me-Too Drug Development: A New Pharma Frontier

    Omics Based Clinical Trials

    Asia Pacific Omics-Based Clinical Trials Market Growth

    AstraZeneca Eyes Acquisition To Develop Cell Therapies

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Robots and AI in Drug

    Robots and AI in Drug Discovery Are Transforming Medicine

    Stringent Policy around COVID Vaccines Laid by FDA

    Stringent Policy around COVID Vaccines Laid by FDA

    Pharmaceutical-Chemicals Market Booms with Rising API Demand

    Pharmaceutical Chemicals Market Booms with Rising API Demand

    Next in Pharma 2025 Innovations

    Next in Pharma 2025: Innovations Shaping the Future

    Work Smart: Go for Hands-Free Lab Informatics at the Bench, Not Scribbled Notes and Delayed Documentation at Your Desk

    Clinical Development

    AI Revolutionizing Drug Discovery and Clinical Development

    Drug-Development

    China’s Super Me-Too Drug Development: A New Pharma Frontier

    Omics Based Clinical Trials

    Asia Pacific Omics-Based Clinical Trials Market Growth

    AstraZeneca Eyes Acquisition To Develop Cell Therapies

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Drug Development Research & Development

Allergan Launches See America , a Bold Initiative Furthering the Fight Against Preventable Blindness

Yuvraj_pawp by Yuvraj_pawp
7th February 2017
in Research & Development

Allergan plc , a global leader in eye care for nearly 70 years, announces a bold commitment to fight preventable blindness in the United States with a new initiative See America.

Through See America, Allergan sets out to make vision health a priority for all Americans, increase awareness of the diseases that can cause preventable blindness and, critically, help improve access to vision care for those who need it most.


The launch follows the release of a major report published in September 2016 by the National Academies of Sciences, Engineering, and Medicine (NASEM), declaring eye health a public health imperative. The report recognized the overwhelming number of Americans affected by blindness from preventable causes. Therefore, NASEM put forth a nationwide rallying cry, encouraging all of America to prioritize proactive eye care.


“Vision loss from diseases such as glaucoma and diabetic retinopathy is affecting and destroying the lives of too many—with cases of preventable blindness increasing at such a frightening rate,” said Herm Cukier, Senior Vice President, Eye Care. “We are launching See America to stress the importance of eye health. The time to act is now.”


Without a nationwide intervention, cases of preventable blindness and visual impairment are projected to double by 20501. At this rate, one American will experience partial or complete loss of sight every four minutes2– costing the U.S. economy trillions of dollars3 over the next thirty-four years.


Through See America, Allergan will partner with the nation’s leading volunteer eye health and safety organization, Prevent Blindness, to champion better access to vision care. Through a series of vision-screening events in various cities, sponsored by Allergan, attendees will receive free one-on-one professional eye exams, follow-up treatment plans and education about the most common diseases affecting people’s vision. In addition to sponsoring Prevent Blindness, Allergan will look to partner on programs from like-minded organizations that support the goals of See America.


Many people are not aware of the perils associated with neglecting their vision. Currently, 61 million Americans are at risk of severe vision loss more than the populations of California and Florida combined4. Yet, only half of those at risk visited an eye doctor in the last year5.


Board Certified Ophthalmologist, Dr. Elizabeth Yeu, believes the key to effective treatment is early detection. “As an ophthalmologist, I’ve seen the endless ways in which vision loss burdens my patients’ lives,” states Yeu. “In certain cases, their vision loss could have been prevented if they had sought out treatment sooner. I’m so happy to be a part of this initiative to shine a spotlight on the problem and rally the support we need to affect change.”6

With an unrivaled eye care portfolio, a national network of medical experts and an unwavering commitment to the future of America’s eyesight, Allergan is standing at the forefront to answer NASEM’s call. For Allergan, this is only the beginning but the message is clear – to fight until the fight has been won.

To learn more about See America and prioritize your own vision, visit www.SeeAmerica.vision.

ABOUT ALLERGAN PLC.

Allergan plc , headquartered in Dublin, Ireland, is a bold, global pharmaceutical company and a leader in a new industry model Growth Pharma. Allergan is focused on developing, manufacturing and commercializing branded pharmaceuticals, devices and biologic products for patients around the world.

Allergan markets a portfolio of leading brands and best-in-class products for the central nervous system, eye care, medical aesthetics and dermatology, gastroenterology, women’s health, urology and anti-infective therapeutic categories.


Allergan is an industry leader in Open Science, the Company’s R&D model, which defines our approach to identifying and developing game-changing ideas and innovation for better patient care. This approach has led to Allergan building one of the broadest development pipelines in the pharmaceutical industry with 70+ mid-to-late stage pipeline programs in development.


Our Company’s success is powered by our more than 16,000 global colleagues’ commitment to being Bold for Life. Together, we build bridges, power ideas, act fast and drive results for our customers and patients around the world by always doing what is right.


With commercial operations in approximately 100 countries, Allergan is committed to working with physicians, healthcare providers and patients to deliver innovative and meaningful treatments that help people around the world live longer, healthier lives every day.
For more information, visit Allergan’s website at www.Allergan.com

 

CONTACTS:

Media:
Mark Marmur
mark.marmur@allergan.com

+1 (862) 261 7558

Suzanne Jacobson
suzanne.jacobson@allergan.com

+1 (201) 427 8879


Lisa DeFrancesco

investorrelations@allergan.com

+1 (862) 261 7152

Previous Post

Arven Pharma selects GE Healthcare to improve Turkish and regional access to biopharmaceuticals

Next Post

Jazz Pharm announces first patient enrolled in phase 2 clinical study evaluating JZP-110

Related Posts

Robots and AI in Drug
Articles

Robots and AI in Drug Discovery Are Transforming Medicine

29th May 2025
Pharmaceutical-Chemicals Market Booms with Rising API Demand
Asia

Pharmaceutical Chemicals Market Booms with Rising API Demand

28th May 2025
Next in Pharma 2025 Innovations
Articles

Next in Pharma 2025: Innovations Shaping the Future

28th May 2025
Insights

Work Smart: Go for Hands-Free Lab Informatics at the Bench, Not Scribbled Notes and Delayed Documentation at Your Desk

27th May 2025
Insights

AstraZeneca Eyes Acquisition To Develop Cell Therapies

24th March 2025
Drug Development

Continuous Bioprocessing Market to Surge by 2028

7th March 2025
Next Post

Takeda Presents $1 Million Gift to the Koch Institute for Integrative Cancer Research

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Subscribe Us

System

  • Search
  • Sitemap
  • RSS Feed

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack
  • Newsletters Archive

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Articles
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In